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https://doi.org/10.1016/j.stemcr.2019.09.005SUMMARYThe regulation of the proliferation and polarity of neural progenitors is crucial for the development of the brain cortex. Animal studies
have implicated glycogen synthase kinase 3 (GSK3) as a pivotal regulator of both proliferation andpolarity, yet the functional relevance of
its signaling for the unique features of human corticogenesis remains to be elucidated. We harnessed human cortical brain organoids to
probe the longitudinal impact of GSK3 inhibition through multiple developmental stages. Chronic GSK3 inhibition increased the pro-
liferation of neural progenitors and caused massive derangement of cortical tissue architecture. Single-cell transcriptome profiling re-
vealed a direct impact on early neurogenesis and uncovered a selective role of GSK3 in the regulation of glutamatergic lineages and outer
radial glia output. Our dissection of the GSK3-dependent transcriptional network in human corticogenesis underscores the robustness of
the programs determining neuronal identity independent of tissue architecture.INTRODUCTION
Neurogenesis is initiated by the formation of a neuroepi-
thelium, composed of neural stem cells (NSCs) organized
in apico-basal orientation that divide symmetrically lead-
ing to a rapid expansion of the NSC pool (Taverna et al.,
2014). The polarization of the neuroepithelium precedes
the differentiation of NSCs into radial glia cells (RGCs),
and triggers the elongation of cytoplasmic processes that
form a migratory scaffold for newborn neurons (Betizeau
et al., 2013). Such polarization is in turn necessary for the
acquisition of the key properties that define tissue organi-
zation (Johansson et al., 2010).
Glycogen synthase kinase 3 alpha and beta (GSK3a and
b) are serine/threonine kinases encoded by two different
genes, which function as integrating hubs formultiple pro-
liferation and differentiation signals due to their central
role in the receptor tyrosine kinase, Wnt and sonic hedge-
hog signaling pathways (Kim et al., 2009; McCubrey et al.,
2016). GSK3 is involved in neurodevelopment through the
phosphorylation of a broad set of substrates, including
transcription factors essential for brain development,
such as CREB (Grimes and Jope, 2001a), neurogenin2
(Ma et al., 2008), b-catenin (Aberle et al., 1997), andThis is an open access article under the Cmultiple microtubule-associated proteins (Fumoto et al.,
2008; Hur and Zhou, 2010). Studies in animal models
have provided a wealth of evidence linking GSK3 activity
to the regulation of early and late neurogenesis in a stage-
wise fashion. Its activity is required to maintain the overall
polarity of the radial glia scaffold (Yokota et al., 2010). Ge-
netic ablation of both GSK3a and GSK3b in RGCs results in
a massive increase in neural progenitor proliferation, with
marked suppression of intermediate progenitor cells (IPCs)
and postmitotic neurons (Kim et al., 2009). However, pa-
ralog-specific knockdown at later stages results in distinct
outcomes, with the loss of GSK3b markedly decreasing
the production of IPCs and upper-layer Cux1-positive neu-
rons (Ma et al., 2017).
Despite the abundant evidence connecting GSK3 to neu-
rogenesis in various animal models, much less is known of
its role in the farmore complex human context,mostly due
to the lack of models that efficiently recapitulate the hu-
man-specific range of progenitor subpopulations. Seminal
work conducted in human embryonic stem cells (hESCs)
demonstrated their proficiency to form 3D aggregates con-
taining self-organized apico-basally polarized cortical tis-
sues with neurogenic properties (Watanabe et al., 2005).
These 3D aggregates are able to generate features usuallyStem Cell Reports j Vol. 13 j 847–861 j November 12, 2019 j ª 2019 847
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Morphogenetic Alterations Caused by Chronic GSK3 Inhibition
(A) Representative captions of cortical organoids at day 18, stained with H&E (magnifications: upper, 103; lower, 633). Scale bars, 200
and 10 mm, respectively.
(B) Representative images from day 18 organoids immunostained with anti-PAX6 (red), anti-KI67 (green), and DAPI (blue), wide-field
fluorescence images. Scale bar, 50 mm.
(C–E) Representative images from day 50 organoids immunostained with: (C) anti-PAX6 (red), anti-Nestin (green), and DAPI (blue), (D)
anti-DCX (white), anti-KI67 (green), and DAPI (blue), and (E) anti-TBR1 (yellow) and DAPI (blue). Scale bars, 50 mm.
(legend continued on next page)
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absent in monolayer cultures, such as specific progenitor
subpopulations and organizing centers (Eiraku et al.,
2008; Kadoshima et al., 2013), constituting the precursors
of current brain organoids protocols. Brain organoids
have emerged as the most promising alternative to model
neurodevelopment under a strictly human genetic back-
ground (Di Lullo and Kriegstein, 2017). Their ontogeny re-
capitulates most of the salient features of early to mid-fetal
brain development, including progenitor populations and
distribution of cell domains (Lancaster et al., 2013; Mariani
et al., 2015, 2012; Pasxca et al., 2015). Single-cell transcrip-
tional profiling of organoids revealed a cellular diversity
that closely matches in composition and transcriptional
landscape the human fetal brain and confirmed the pres-
ence of human progenitor populations responsible for
neocortical expansion (Amiri et al., 2018; Camp et al.,
2015; Quadrato et al., 2017).
Here we explore the role of GSK3 on early to middle cor-
ticogenesis through the chronic and specific inhibition of
its activity in human cortical organoids. By combining
morphological characterization with massive parallel
RNA sequencing (RNA-seq) on bulk and single cells, we un-
cover the molecular pathways modulated by GSK3 and
break down its effect on distinct cell subpopulations of
the developing human cortex, revealing a differential
impact on neuronal progenitor subtypes and outer radial
glia (oRG) output.RESULTS
GSK3 Is Essential for Cortical Organoid
Morphogenesis
Patterned cortical organoids follow a stereotypicalmorpho-
genesis beginning with RGCs aligned in three dimensions
around ventricle-like structures (VLS), mimicking the hier-
archical organization of the ventricular zone of the dorsal
telencephalon. Polarized RGCs are evident by day 18 (Fig-
ure 1A), with NESTIN+/PAX6+ cells comprising about
80% of the population (Figure 1B). This proportion de-
creases over time and becomes restricted to well-confined
proliferative domains that gradually generate the neurons
of the cortical plate (Pasxca et al., 2015). To investigate the
role of GSK3 activity throughout corticogenesis, we chron-
ically exposed cortical organoids to the most specific GSK3
inhibitor available CHIR99021 (termedCHIRhereafter) at a
1 mMconcentration, selected below the threshold for endo-
dermal or mesodermal lineage induction in hPSCs (Patsch(F and G) Quantification of the proportion of PAX6+ nuclei relative to
(H and I) Quantification of the proportion of KI67+ nuclei relative to
(J) Quantification of the proportion of TBR1+ nuclei relative to total n
in five organoids per line, three independent hPSC lines (N = 15, n =et al., 2015). Chronic GSK3 inhibition resulted in an in-
crease in organoid size (Figures 1A and 2F) concomitant
with a virtually complete loss of VLS (Figures 1A and 1B),
with a stronger effect by day 50 (Figures 1C–1E). Unexpect-
edly, this difference in organoid size and radial organiza-
tion was accompanied by a marginal decrease of PAX6+
cells at day 18 (Figure 1F) (CTL 76 ± 3.3, CHIR 65 ± 2.7),
as well as of its expression levels (Figure S1A), while no sig-
nificant differencewas observed at day 50 in the proportion
of PAX6+ cells (Figure 1G) (CTL 20 ± 1.2, CHIR 22 ± 1.0).
Moreover, staining of early neuron markers TBR1 (layer
V–VI neuronal progenitors) (Figure 1E) and DCX (Fig-
ure 1D) revealed a profound disarray in tissue architecture
with only a slight reduction in TBR1+ cells (CTL 39 ± 1.3,
CHIR 32 ± 1.3) (Figure 1J), indicating that GSK3 activity is
critical for the correct morphogenesis of the developing
cortex.
To dissect the mechanisms underlying this morphogenic
defect, we adopted a two-tiered strategy: (1) a validation in a
classic 2Dmodel attuned to quantify essential properties of
NSCs such as polarity and proliferation (Conforti et al.,
2018); and (2) transcriptional profiling of patterned cortical
organoids at 18, 50 and100days for adynamic characteriza-
tion of early corticogenesis (Figure 2A). We followed the
emergence of 2D neural rosettes until 20 days in vitro,
when rosettes are typically PASL1+ at the apical end.
GSK3 inhibition drastically reduced rosette number (Fig-
ures 2B and 2C) as well as the average size of formed rosette
lumens (Figure 2D). Likewise, a growth curve for 72 h re-
vealed an increase in proliferation rate up to 1.5-fold
compared with control (Figure 2E), indicating that both
the morphogenic disarray and the increased size observed
in early cortical organoids arise from aberrations already
present during the transition from pluripotency to NSCs.
In addition, we quantified the impact of GSK3 inhibition
on organoid size through a growth measurement over a
40-day time course. We found a sustained increase in orga-
noid size upon chronic GSK3 inhibition (Figures 2F–2H),
with a robust surge in pace between days 10 and 15, subse-
quent to the time pointwhen cortical organoids begin to be
exposed to proliferation-boosting factors, fibroblast growth
factor 2 and epidermal growth factor (Figure 2H), in agree-
ment with the increased proliferation rate observed at the
first 72 h of neural induction (Figure 2E) and pointing to a
growth factor-mediated proliferation process.
A previous report suggested that the sustained applica-
tion of CHIR99021 in forebrain organoids after day 12 of
differentiation decreased the number of Caspase 3+ coretotal nuclei (DAPI) at (F) day 18 and (G) day 50 of differentiation.
total nuclei (DAPI) at (H) day 18 and (I) day 50 of differentiation.
uclei (DAPI) in day 50 organoids. All quantifications were performed
3), unpaired t test; *p < 0.05, **p < 0.01, ***p < 0.001.
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cells (Qian et al., 2016), which could explain the increase in
organoid size. To test whether chronic CHIR application
had an overall effect on cell viability, we performed lumi-
nescent quantitation of membrane permeability in day
50 organoids every 24 h, during 72 h of growth factor star-
vation.Quantification showed no changes in cell death as a
result of GSK3 inhibition, either in baseline (0 h) or after
72 h of starvation (Figures 2I and 2J), indicating that
chronic GSK3 inhibition has no impact on basal or starva-
tion-mediated cell death, hence excluding reduced
apoptosis as a plausible cause of the increased organoid
size. Instead, quantification of the proliferation marker
Ki67 showed a marked increase of actively dividing
cells in organoids at day 18 (CTL 10 ± 0.7, CHIR 19 ± 1.3)
(Figure 1H) and day 50 (CTL 4.3 ± 0.4, CHIR 8.0 ± 0.8) (Fig-
ure 1I) pointing to the regulation of progenitor prolifera-
tion as a core effect of GSK3 activity.
Transcriptional Regulation Associated to GSK3
Activity throughout Cortical Development
Abundant evidence supports an active role of GSK3 in neu-
rogenesis (Hur and Zhou, 2010); however, since complete
GSK3 ablation causes systemic failure and early embryonic
lethality (Hoeflich et al., 2000), its levels/activity are usu-
ally manipulated both in vitro and in vivo after the early
stages of neurodevelopment have already been completed.
The surprisingly mild effect of chronic GSK3 inhibition on
neural maturation prompted us to dissect its role on gene
expression by bulk RNA-seq at three critical time points
recapitulating relevant stages of human cortical develop-
ment (i.e., day 18: abundant apical radial glia; day 50: pres-
ence of intermediate progenitors and early neurons; and
day 100: presence of lower layer neurons and beginning
of astrogenesis) (Pasxca et al., 2015).Figure 2. GSK3 Inhibition Disrupts Lumen Organization and Prog
(A) Experimental design: hPSCs differentiated following two parallel
inhibition. In both cases, parallel rounds were either exposed or not
indicated sample collection time point.
(B) Representative captions from immunostaining performed for
acquisition, 203. Scale bar, 50 mm (zoom panel, 10 mm).
(C) Bar plots represent the average lumen number ± SD of five indep
(D) Lumen area quantification was performed by CellProfiler software
(E) Cell proliferation rate was estimated by CellTiter-Glo luminescenc
independent hPSC lines (n = 3).
(F) Representative bright-field captions of day 40 organoids. Scale b
(G) Growth curve performed in organoids differentiated for 40 days. B
40. Points represent the average of 4 organoids per line. Size quantifi
(H) Derivative of the growth-rate delta between time points. The delt
was calculated as a cumulative SD across all replicates and samples from
measured per line/time point (N) (N = 72, n = 3), unpaired t test; **
(I) Representative images from day 50 organoids stained with CellT
starvation (depletion B27 and growth factors). Scale bar, 200 mm.
(J) Quantification of CellTox fluorescence at 0, 24, 48, and 72 h afteA dissection of the most influential genes on component
1 of principal-component analysis identified genetic
drivers of cell proliferation as main source of variability
(Figures 3A and S3A) and highlighted the stronger impact
of CHIR treatment at days 50 and 100. A survey of gene sig-
natures defining specific stages of differentiation (active
proliferation, early and late RGs, early and late neurons)
(Figure S1) confirmed a sustained increase of the prolifera-
tionmarkerMKI67 upon CHIR treatment at days 18 and 50
(Figure S1A–S1C), alongwith an upregulation in genes con-
trolling distinct aspects of cell-cycle progression at days 50
and 100. Notably, we observed a robust upregulation of the
anaphase promoting complex/cyclosome (APC/C), CDC20
(Figures S1B and S1C), which has been implicated in
the modulation of the synaptic connectivity regulator
NEUROD2 levels through the regulation of its ubiquitina-
tion (Yang et al., 2009). Intriguingly, despite the strong
proliferation effect, the expression levels of canonical
neuronal markers (DCX, MEF2C, STMN2) (Figures S1B
and S1C), cortical layer makers (POU3F2, CUX1, BCL11B),
and ventral fate determinants (DLX1-2, ARX, GAD1-2,
ASCL1) (Figures S2A–S2C) showed either mild or no differ-
ences, whereas the neuron-specific microtubule-related
genes showed differential modulation upon CHIR inhibi-
tion (i.e., upregulation of TUBB3 and downregulation
MAP2) (Figures S1B and S1C). Likewise, we observed a
strong downregulation of NEUROD2 expression at days
50 and 100 (Figures S1B and S1C), which could in turn
explain the downregulation of several glutamate channel
subunits observed at day 100 (Figures S1C and S1D).
To address the functional implications of chronic CHIR
exposure, we performed stage-wise differential expression
analysis (DEA) (Figures 3B–3D). DEA confirmed the stron-
gest CHIR effect at day 50, with 898 differentially expressedenitor Proliferation Rate
protocols, in 3D (up) cortical organoids or 2D (down) dual-smad
to GSK3 inhibitor CHI99021 (1 mM) starting from day 0 until the
anti-Pals1(green)/Hoechst(blue), wide-field fluorescence images
endent images for lines/conditions.
; unpaired t test; **p < 0.01, ***p < 0.001, ****p < 0.0001.
e assay, with measurements every 24 h for 96 h in triplicate, three
ar, 500 mm.
right-field captions were taken at days 5, 9, 14, 20, 24, 30, 35, and
cations were performed with a custom-made FIJI function.
a was computed on the average of untreated or treated samples. SD
each condition of three independent hPSC lines (n), four organoids
p < 0.01, ****p < 0.0001.
ox green as a marker of cytotoxicity after 72 h of growth factor
r growth factor starvation.
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genes (DEGs) (Figure 3C) (full list of DEGs, Table S2).
Ontology analysis revealed a persistent upregulation of cat-
egories linked to cell proliferation and DNA replication
(nucleosome assembly) and a downregulation of cell sur-
face components, as well as ion channels, including
AMPA subunits (Figures S3C and S3D). While there were
no DEGs preserved at all stages upon CHIR treatment, we
identified 9 DEGs consistently dysregulated in the day
18 / day 50 transition and 54 DEGs in the day 50 /
day 100 transition (Figure 3E). Interestingly, day 18 /
day 50 shared DEGs included the upregulation of neurite
outgrowth factors (NEFM, NCL, and RAB13), and downre-
gulation of the brain morphogenesis modulator (PTCHD1)
(Figure 3F), whereas the day 50/ day 100 dysregulation
featured an abundant upregulation of protein translation
and replication regulators (Figure 3G). The overall compar-
ison of gene modulation across stages showed a stronger
preservation in the fold changes trends between day 50
/ day 100 (R = 0.62) compared with day 18 / day 50
(R = 0.45), despite the longer time span and increased
cell-type diversity at later stages (Figures 3F and 3G), sug-
gesting a more robust dependency of GSK3 activity occur-
ring during this transition.
To gain deeper insight into the coordinated modulation
of functionally related genes induced by GSK3 inhibition,
we performed gene set enrichment analysis (GSEA). This
approach confirmed a robust enrichment for pathways
targeted by GSK3 activity (MTORC1, Myc signaling) and
narrowed down the upregulation of G2-M transition
modulators as a persistent feature of GSK3 transcriptional
impact at all stages (Figures 3H–3J). Likewise, several of
the identified GSEA categories (complete list in Table
S3) are directly linked to the observed phenotypes,
including the increased progenitor production (mamma-
lian target of rapamycin complex 1 pathway), changes of
cell polarity (mitotic spindle orientation) and neuronal
fate (Wnt-b-catenin pathway). Interestingly, both geneFigure 3. Impact of GSK3 Inhibition on the Transcriptional Lands
(A) Principal component analysis performed on the whole transcriptom
development: days 18, 50, and 100.
(B–D) Volcano plots illustrating the differential expression analysis fo
are reported for the pool of tested genes as –log10 false discovery rat
modulated (FDR < 5% and absolute log2FC > 1) are shown in green, wh
not significant genes (FDR > 5%) in gray. Gene symbols highlight the to
in each stage.
(E) Venn diagram depicting the overlap of modulated genes across d
(F and G) Scatterplots representing the relationship of the fold change
y axis (F) or day 50 on the x axis and day 100 on the y axis (G), for the
two examined conditions are reported in yellow, while DEGs specific
Correlation coefficient calculated according the Spearman metrics––0
(H–J) Gene expression profiles for selected gene sets significantly asso
day 100. Expression levels (as Z score) for the top 10 ranking genes in
done in three independent hPSC lines/time point (N = 18, n = 3).ontology analysis at day 50 and GSEA (at all stages) point
to the downregulation of inflammatory pathways by
GSK3 inhibition, in line with a recognized role of GSK3
as mediator of neuroinflammation (Grimes and Jope,
2001b).
Cortical Organoids Recapitulate the Main Features of
Mid-fetal Human Corticogenesis at the Single-Cell
Level
Given the greater transcriptional impact of GSK3 observed
at the day 50/ day 100 transition, we harnessed single-
cell transcriptomics combined with distance-based analyt-
ical tools to break down the effects of CHIR exposure in
terms of population frequencies and developmental trajec-
tories found during this time frame. We carried out
droplet-based single-cell mRNA-seq to profile over 30,000
cells (N = 33293) in 11 biological samples from unexposed
and exposed cortical organoids at day 50 and day 100 of
differentiation, attaining 15 unsupervised cell clusters
defined using the Louvain modularity algorithm (Subelj
and Bajec, 2011). By projecting the expression levels of ca-
nonical population markers over uniform manifold
approximation and projection (UMAP) (Figures 4A and
4B), combined with the overlap of cluster-specific genetic
signatures from single-cell RNA-seq datasets of fetal hu-
man brain samples (Nowakowski et al., 2017) (Figure S4)
and considering their position over diffusion map (Fig-
ure 4C), we grouped the Louvain clusters into five main
population identities, including proliferating RG, IPCs
(including a discernible subset of oRG), early neurons, neu-
rons, and choroid. We then investigated the underlying
developmental trajectories using a diffusion map algo-
rithm (Coifman et al., 2005) (Figures 4C and 4D). This
confirmed the presence of a hierarchical progression
from RGs to postmitotic neurons linked by intermediate
populations (Figure 4C). The application of pseudotime
for lineage-branching reconstruction (Haghverdi et al.,cape
e of untreated and CHIR-treated brain organoids at three stages of
r CHIR treatment at day 18 (B), day 50 (C), and day 100 (D). Results
e (FDR) and log2 fold change (FC). Genes identified as significantly
ile those respecting only the FDR threshold are depicted in blue and
p 10 upregulated and downregulated genes (ranked by fold change)
evelopmental stages.
induced by GSK3 inhibition at day 50 on the x axis and day 18 on the
subset of genes tested in both conditions. DEGs shared between the
for days 18, 50, or 100 are in green, blue, or violet, respectively.
.45 in (F) and 0.62 in (G).
ciated with CHIR treatment by GSEA: (H) day 18; (I) day 50; and (J)
the leading edge are visualized for each gene set. All analyses were
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Figure 4. Cortical Organoids Recapitulate the Main Features of Cortical Development
(A) Louvain clusters in UMAP plot colored by cluster identity; lines depict population areas defined by contrast with markers obtained from
human fetal brain dataset (radial glia, 8, 13, and 14; intermediate progenitor cells, 2, 7, and 12; outer radial glia, 4; early neurons, 5 and
10; neurons, 0 and 1; choroid 11).
(B) UMAP plots. For each sub-panel, cells (represented as dots) are colored according to the expression levels of representative cell-type
markers: STMN4, GNG3, DCX, neurons; HOPX, PTPRZ1, FAM107A, outer radial glia; DLL1, DLL3, ROBO3, early neurons; SMOC1, IFITM3, HES1,
intermediate progenitors; AURKA, UBEC2C, TACC3, proliferating progenitors; CXCL14, PLS3, TTR, choroid.
(C and D) Diffusion map representing the developmental trajectory of the system. Cells (dots) are colored according to cluster identity (C)
and to pseudotime trajectory (D), from origin in black to terminal state in light yellow according to wishbone algorithm.
(E) Visualization of the expression levels of representative genes along pseudotime: CDK1 and MKI67, proliferating progenitors; DCX and
STMN2, neurons; HOPX, outer radial glia; SMOC1, intermediate progenitors. Analyses done in 33,293 cells from 6 hPSC lines from day 50 and
5 hPSC lines from day 100.2016; Setty et al., 2016), with an origin anchored in the
early progenitors, reproduced the organization of popula-
tions from RG to neurons (Figure 4D). Likewise, the distri-
bution of expression of specific population markers
confirmed the presence of a lineage path from RGs
through the IPC-oRG transition and into early and late854 Stem Cell Reports j Vol. 13 j 847–861 j November 12, 2019neural maturation stages (Figure 4E). Together, these re-
sults confirm that patterned cortical organoids recapitulate
cardinal features of human corticogenesis, including the
presence of early and intermediate progenitors, the emer-
gence of oRGs and their hierarchical positioning in neuro-
genic trajectories.
GSK3 Inhibition Differentially Affects Specific
Domains of Corticogenesis
A comparative analysis of subpopulations revealed a selec-
tive impact of GSK3 inhibition on the relative proportion
of specific cell subtypes (Figures 5A–5H). A salient effect
was the almost complete loss of a subpopulation character-
ized by the expression of genes expressed in choroid cells
(CXCL14, TPD52L1, PCP4, EMX2) (Figures 5A and 5B),
as well as a noticeable decrease in frequency (FQ) of
NEUROD2-expressing cells at day 100 in neuronal clusters
(0, 1, 5) without affectingNEUROD6- orNEUROG2-express-
ing cells (Figures 5C and 5D), underscoring the selectivity
of GSK3 activity on these neurogenic pathways. It is worth
noting that analysis of the frequency and distribution of
cells expressing a canonical oRG gene signature (HOPX,
TNC, FAM107A, PTPRZ1) (Pollen et al., 2015) (Figures 5E
and 5F), showed a marked reduction in both frequency
and expression levels upon CHIR treatment at day 100,
whichwas further confirmed by a reduction ofHOPX+ cells
in the tissue (Figure 5I). Given the cardinal role of oRG on
neuronal production and cortical expansion, we checked
the distribution of expression of telencephalic markers,
including forebrain determinant (FOXG1), early neurons
(DCX), lower-layer (BCL11B, RBFOX3), and upper-layer
(SATB2, POU3F2) markers. Whereas upper-layer markers
were either not detected or present at very low frequencies,
consistent with their surge at later stages of organoid corti-
cogenesis, the expression of lower layer and general
neuronal identity markers was unchanged by CHIR (Fig-
ure 5H), whereas FOXG1 was significantly reduced at day
50 (Figures 5G and 5H). Interestingly, despite the mild
changes frequency and expression levels of BCL11B at
day 50 and day 100 (Figures 5H and S2), staining for its pro-
tein product (CTIP2)+ cells showed a drastic reduction in
day 100 CHIR-treated organoids (Figure 5I), pointing to
regulatory mechanisms at the post-transcriptional level re-
ported to affect CTIP2 activity and stability (Selman et al.,
2018; Zhang et al., 2012).
Next, to study the temporal associations between popu-
lations, we performed pseudotime analysis. The analysis
of cell-type distribution across pseudotime uncovered a
higher proportion of cells in both progenitor and mature
areas upon chronic GSK3 inhibition at day 50 (Figure 6A).
This result was compatible with two possibilities: (1) the
cells identified as mature by predefined gene signatures
could actually turn out to display mixed identities, co-ex-
pressing both progenitor and maturation markers as a
result of a fundamental derangement of developmental hi-
erarchies; or (2) the highly proliferative progenitors from
CHIR-treated organoids undergo a faster transition
through the intermediate stages or even skip them alto-
gether. To test these hypotheses, we plotted proliferating/
maturity signatures into UMAP and found no evidence ofoverlap in CHIR-treated organoids (Figure S5A); likewise,
we did not observe an overlapping distribution between
Ki67+ and DCX+ cells (Figure 1D), thus ruling out the pos-
sibility of a prevalent mixed identity. Instead, the contour
plot (Figure 6A) pointed to a reduction in the intermediate
populations in CHIR-treated organoids at days 50 and 100,
consistent with the higher proportion of mature cells
found at the same developmental stage (Figure 6A). Next,
to further investigate the relations between populations,
we used partition-based graph abstraction as a way to esti-
mate the strength of connectivity across the cells belonging
to each cluster, thus inferring transitional links among
subpopulations. This approach confirmed a decrease of
connections between intermediate progenitor clusters
(yellow), including oRG, upon GSK3 inhibition, particu-
larly evident at day 100 (Figure 6B), corroborating a
CHIR-dependent overall reduction of the intermediate to
maturity transition.
Finally, the application of pseudotime, independently to
all conditions and stages, revealed two developmental tra-
jectories, one that goes from RG to neurons through a sub-
set of IPCs and one that becomes apparent by day 100 and
ends in an oRG identity (Figure 6C). Strikingly, GSK3 inhi-
bition resulted in a complete loss of the oRG-generating
trajectory at day 100 (Figure 6C), an effect that could be re-
produced bidirectionally by decomposing each trajectory
into first and second components (Figure S5B). In agree-
ment, HOPX distribution of expression on pseudotime
peaked at day 100 in control organoids, while it remained
stalled in day 100 CHIR-treated organoids (Figure 6C).
Together, these results suggest that GSK3 inhibition results
in a severe reduction of HOPX-expressing cells with the
attending impact on oRG-dependent lineages.DISCUSSION
This work provides the first dissection of the role of GSK3
activity throughout early to mid-fetal corticogenesis in a
human background. Specifically, our integrated analysis
of tissue and transcriptional regulation at single-cell resolu-
tion uncovers a key role for GSK3 activity in cortical tissue
architecture, with a differential impact on neuronal output
vis-a-vis a strong decrease of oRG production.
GSK3 activity has been implicated in the regulation of
neocortical neuron production, with pronounced impact
at late stages (Li et al., 2012), consistent with the increased
transcriptional dysregulation that we observe in days 50 to
100 cortical organoids. Our in-depth transcriptional anal-
ysis indicates that not all aspects of cortical neurogenesis
are equally affected, even in the face of the early increase
in progenitor proliferation and massive morphologic
disarray, which emphasizes the resilience and degree ofStem Cell Reports j Vol. 13 j 847–861 j November 12, 2019 855
Figure 5. Effects of GSK3 Inhibition at a Single-Cell Level in Day 50 and 100 Cortical Organoids
(A–H) Visualization of normalized expression levels for genes identifying specific populations either in UMAP divided by CHIR-treated and
control samples (A, C, E, and G). Sub-sampled cluster-specific expression levels (violin plots), Fisher test; ***p < 0.001, **p < 0.01, *p < 0.05.
FQ, normalized cell frequencies of cells expressing detectable levels/total population (bar plots) (B, D, F, and H). The following genes are
examined: (A and B) CXCL14 in UMAP and CXCL14, PCP4, TDP52L1, EMX2 in violin plots on cluster 11 for choroid population; (C and D) NEUROD2
in UMAP and NEUROD2, NEUROD1, NEUROG2, and NEUROD6 on clusters 0, 1, and 5 for neuronal markers; (E and F) HOPX in UMAP and HOPX, TNC,
FAM107A, and PTPRZ1 on cluster 4 for oRG markers; (G and H) FOXG1 in UMAP and FOXG1 (total) and BCL11B, RBFOX3, and DCX on clusters 0, 1,
and5 for dorsal telencephalonmarkers. Sub-samplinghasbeenapplied in order to randomly compare an equal numberof cells for eachcategory.
(I) Representative wide-field fluorescence images from day 100 organoids immunostained with anti-CTIP2 (red), anti-HOPX (gray), and
DAPI (blue). Scale bar, 20 mm.
(J) Semiquantitative estimation of HOPX positive cells/DAPI area. Quantification corresponds to three organoids per line, three inde-
pendent hPSC lines. Analyses done in 33,293 cells from 6 hPSC lines from day 50 and 5 hPSC lines from day 100.
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Figure 6. Effects of GSK3 Inhibition at a Single-Cell Level in Day 50 and Day 100 Cortical Organoids
(A) Contour plot representing the difference in frequency distribution in clusters and pseudotime intervals of treated versus untreated cells
at days 50 and 100. Red depicts values higher in CHIR-treated cells, while blue depicts values higher in CTL-treated cells.
(B) Partition-based graph abstraction analysis applied stage- and treatment-wise on the 15 clusters identified on the complete dataset.
Circle diameter represents the fraction of cells assigned to each cluster; edge thickness visualizes the strength of connections across cells
of the related clusters. Shadows highlight areas: progenitors (green), neurons (blue), and intermediate progenitors (yellow).
(C) Over-imposition of pseudotime analyses performed separately for each experimental condition as a color scale on a UMAP calculated on
the complete system. Blue (origin) and dark red (terminal state) according to wishbone trajectories. Visualization of the expression levels
of representative genes along the condition-specific pseudotime. Analyses done in 33,293 cells from 6 hPSC lines from day 50 and 5 hPSC
lines from day 100.
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cell autonomy of the transcriptional programs involved in
neuronal identity, even against the disruption of stereotyp-
ical tissue architecture. In particular, early neuronal driver
NEUROD2 was strongly downregulated in bulk transcrip-
tomes and remained reduced both, in terms of expression
levels and frequency in single cells, concomitantly with a
reduced number of cells positive for low-layer markers
TBR1 and CTIP2, while the frequency of cells expressing
neurogenic drivers (NEUROG2), fetally expressed pan-
neuronal markers (DCX, STMN2), and low-layer determi-
nants (RBFOX3, CUX1) was either unchanged or only
slightly differed in expression levels among very low cell
frequencies. Interestingly, we found a decrease in FOXG1
levels at day 18 bulk transcriptomes and in the frequency
of FOXG1-expressing cells at day 50. These changes in
FOXG1 expression resulted in no evident posteriorizing ef-
fects, likely reflecting the minute fraction of FOXG1-posi-
tive cells at days 50 to 100 (consistently with its expression
peaking at day 25; Birey et al., 2017) and the cortical orga-
noid patterning that drives toward a telencephalic fate
(Pasxca et al., 2015). In light of the emerging disconnect be-
tween transcript and protein levels of several neurogenic
transcription factors due to post-transcriptional regulation
(Yoon et al., 2017), it will be interesting to determine the
short- to long-term impact of such transcriptional alter-
ations on the respective protein effectors.
Depletion of GSK3 activity using pharmacological inhi-
bition or knockdown causes drastic changes in radial glial
organization (Yokota et al., 2010). As polarization of radial
glia is a prerequisite for cortical scaffolding, neuronal
migration, and layering (Shah et al., 2017), its alterations
result in impaired cortical plate formation (Beattie et al.,
2017; Shah et al., 2017). The effects of GSK3 in radial glia
organization constitute fast cellular responses triggered
by phosphorylation of targets such as CRMP2, MAP1B,
and CLASP, which in turn affects modifications and struc-
tural changes in microtubule cytoskeleton (Hur and
Zhou, 2010; Yokota et al., 2010). We did not observe any
differences in expression of canonical polarity markers or
determinants of radial glia organization (data not shown);
thus, in the human setting, the sustained morphological
defects caused by GSK3 activity inhibition are not caused
by transcriptional regulation of polarity determinants.
Rather, the most salient transcriptional global effect was
the upregulation of modulators of cell replication and, in
particular, the G2M transition emerged as a recurrent target
at all stages, indicating that themodulation of the G2M is a
persistent feature of GSK3 activity throughout human
corticogenesis.
During human corticogenesis, the bulk of neuronal pro-
duction comes via IPCs that originate from RGs and are
located in the subventricular zone (Bystron et al., 2008; Flo-
rio and Huttner, 2014). Spatiotemporal regulation of GSK3858 Stem Cell Reports j Vol. 13 j 847–861 j November 12, 2019activity is required for an appropriate transition from the
proliferative to the neurogenic phase occurring during
brain development (Kim et al., 2009). In our chronic
setting, starting from a pluripotent state (day 0), GSK3 inhi-
bition caused increased proliferation and polarity defects in
NSCs, reflected also in larger organoid size. The dramatic
increase in CHIR-dependent transcriptional dysregulation
at day 50, compared with day 18, indicates that the early
defects in NSCs are amplified in intermediate and
committed progenitors, and suggests a higher reliance on
GSK3 activity at later stages and stronger in IPCs. In agree-
ment, the population breakdown by single-cell analysis re-
vealed a decrease of IPCs and in particular oRGs.
Pseudotime trajectories showed that cortical organoids
recapitulate the co-existence of a direct neurogenic trajec-
tory, visible by day 50, that is juxtaposed to an indirect tra-
jectory reaching an oRG identity by day 100, in agreement
with a protracted wave of neurogenesis dependent on oRG
production, known to be a salient feature of primate corti-
cogenesis and responsible for lateral expansion of the hu-
man cortex (Bershteyn et al., 2017; Florio and Huttner,
2014). In sum, the disappearance of the indirect neuro-
genic trajectory at day 100 upon CHIR treatment points
to a key role of GSK3 in the establishment of IPC/oRG pop-
ulations. Our results thus indicate that, in humans, while
GSK3 activity selectively contributes to different early
RG-derived neuronal identities, it is pivotal for the later
generation of oRG with the ensuing outcome in terms of
oRG-dependent lineages.EXPERIMENTAL PROCEDURES
hPSC Culture
Five different hPSC lines from different backgrounds (one ESC and
four iPSCs) were used across all conducted experiments (relevant
ethics approvals are referred to in the original publications report-
ing their first use and/or derivation). The culture conditions of
hPSCs are described in Supplemental Experimental Procedures.
Distribution of lines across experiments is delineated in Table S1.
Neural Induction in 2D and Lumen Quantification
Three biological replicates were analyzed for untreated and treated
cells. From day 0 of neural induction, CHIR99021was added to the
medium at 1 mM concentration in parallel with neural induction
withDMSOuntil day 20. At day 12, cells weremoved to neuralme-
dium containing DMEM/F12 (Life Technologies) with N2 and B27
plus retinoic acid and 30 ng/mL brain-derived neurotrophic factor.
Differentiation process and immunostaining procedure are
described in Supplemental Experimental Procedures.
Proliferation Assay
Number of viable proliferating cells was estimated by lumines-
cence assay CellTiter-Glo (Promega). In brief, 2 3 103 cells/well
were plated in 96-well flat bottom plates (Corning) with 4
replicates per condition and left to proliferate for 96 h. Measure-
ments were performed every 24 h. Each data point was normalized
to a blank from unseeded wells.
Cortical Organoid Differentiation and Inhibition
Cortical organoids were differentiated as described previously
(Pasxca et al., 2015). A detailed protocol is given in Supplemental
Experimental Procedures. ChronicGSK3 inhibitionwas performed
by adding CHIR99021 (Merck SML1046) to the medium at day
0 (1 mM) and kept throughout the differentiation process until
reaching the respective collection time points.
Growth Curve
Organoids were moved at day 0 to 96-well U-bottom ultra-low
attachment plates (Corning) and kept individually to avoid fusions
for image acquisition until day 12 of differentiation. From day 12
onward, organoids were moved individually to 24-well ultra-low
attachment plates (Corning). Images were acquired with an
EVOS Cell imaging System XL (Thermo) at the indicated differen-
tiation days. Organoid size was calculated using an in-house devel-
oped custom-script (by C.E.V.) for FIJI software (v.1.49; NIH, USA).
Tissue Preservation and Staining
Organoids were fixed in 4% (vol/vol) paraformaldehyde for a min-
imum of 2 h for day 18 organoids to overnight for day 50 and day
100 organoids. Fixed organoids were washed twice with PBS and
mounted onOCTcryopreservationmediumondry ice. Cryoblocks
were preserved at80C until themoment of sectioning. Cryosec-
tions were prepared using Leica CM 1900 instrument with 5 mm
thickness. Sections were incubated with 10 mM sodium citrate
buffer (Normapur) for 45 min at 95C + Tween 20 0.5% for simul-
taneous antigen retrieval and permeabilization. Antibody incuba-
tion details and image acquisition and quantification details are
given in Supplemental Experimental Procedures.
Total RNA Extraction and Sequencing
Total RNA was isolated with the RNeasy Micro Kit (QIAGEN, Hil-
den, Germany) according to the manufacturer’s instructions.
RNA was quantified with Nanodrop and then the integrity was
evaluated with Agilent 2100 Bioanalyzer. A TruSeq Stranded Total
RNA LT Sample Prep Kit (Illumina) was used for library preparation
starting from 500 ng of total RNA for each sample. Sequencing was
performed with the Illumina NOVAseq 6000 platform, with an
average depth of 35 million 50 bp paired-end reads per sample.
Bulk Transcriptome Analysis
Three biological replicates were analyzed for untreated and treated
organoids at each time point, for a total of 18 samples subjected to
bulk RNA-seq. The detailed analytical pipeline is described in Sup-
plemental Experimental Procedures.
Single-Cell Suspension, cDNA Synthesis, Library
Preparation, and Sequencing
Organoids were collected at days 50 or 100. Three to 5 organoids
per condition were dissociated by incubation with a solution of
0.5 mg/mL trypsin + 0.22 mg/mL EDTA (Euroclone) with 10 mLof DNaseI 1,000 U/mL (Zymo Research) for 30–45 min according
to organoid size. Digested suspensions were passed once through
0.4-mm Flowmi cell strainers, resuspended in PBS and counted us-
ing a TC20 automatic cell counter (Bio-Rad). Droplet-based single-
cell partitioning and single-cell RNA-seq libraries were generated
using the Chromium Single-Cell 30 Reagent v2 Kit (103Genomics,
Pleasanton, CA) following the manufacturer’s instructions.
Detailed library preparation is given in Supplemental Experi-
mental Procedures.
Single-Cell Transcriptome Analysis
Eleven biological samples (day 50, 3 untreated and 2 treated; day
100, 4 untreated and 2 treated) were examined by single-cell anal-
ysis, for a total of 33,293 cells and a median of 1,733 features for
cells. Libraries from single-cell sequencing were aligned relying
on the CellRanger v2.1 pipeline and using hg38 as reference. Array
express accession number: E-MTAB-8337. Detailed single-cell
transcriptome analysis is given in Supplemental Experimental
Procedures.
Statistical Analysis
Statistical analyses were done using PRISM (GraphPad, version
6.0). Statistical significance was tested with the unpaired t test,
considering each hPSC line as biological replicates (n) and total
number of organoids per line (N). Treatments tested as variables.
p values and significance, n and N are reported in each figure
and legend. All results were expressed as means ± SD. No data
points were excluded from the reported analyses.
ACCESSION NUMBERS
The accession number for the bulk RNA seq reported in this paper
is ArrayExpress: E-MTAB-8325. The accession number for the
single-cell RNA seq reported in this paper is ArrayExpress:
E-MTAB-8337.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2019.09.005.
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1. Supplemental figure legends 
Figure S1. Expression profiles for gene signatures defining specific developmental stages. Related to Figure 3. 
Stripcharts for expression levels (in log2cpm) from bulk RNA sequencing at day 18 (A), day 50 (B) and day 100 (C). 
Unexposed samples are visualized in turquoise, CHIR-exposed samples in orange. Blue and red boxes highlight 
respectively genes down- or up-regulated by CHIR treatment, considering the following thresholds from RNASeq 
bulk differential expression analysis: *: nominal p-value < 0.05; **: nominal p-value < 0.01; ***: FDR < 0.05 and 
absolute log2FC > 1.  
Figure S2. Expression profiles for genes related to dorsalising/ventralizing fate. Stripcharts for expression levels 
(in log2cpm) from bulk RNA sequencing at day 18 (A), day 50 (B) and day 100 (C). Unexposed samples are visualized 
in turquoise, CHIR-exposed samples in orange. Blue and red boxes highlight respectively genes down- or up-regulated 
by CHIR treatment, considering the following thresholds from RNASeq bulk differential expression analysis: *: 
nominal p-value < 0.05; **: nominal p-value < 0.01. 
Figure S3. Breakdown of stage-wise differential expression analysis. Related to Figure 3. A. Top-100 genes 
according to absolute loading value for the first component from Principal Component Analysis. B. Results of gene 
ontology enrichment analysis performed for Biological Process GO domain on the 100 genes selected as detailed in 
A; p-values for the top-10 categories are shown. C. Gene expression profiles (as z-scores) for the genes identified in 
bulk RNASeq as modulated by GSK3 treatment (FDR < 0.05, absolute log2FC > 1) at day 18 (A), day 50 (B) and day 
100 (C). D. Results of gene ontology enrichment analysis performed on the DEGs identified at day 50, divided for up-
regulated and down-regulated genes. Bar plots depict the p-values for the top-10 Cellular Component GO terms.  
Figure S4. Overlap of Louvain clusters to cell identities within human fetal data single cell transcriptomes. 
Related to Figure 4. A.  For each sub-panel, cells (represented as dots) are colored according to the expression levels 
of paired combinations of representative cell type markers (DCX, STMN2 = mature neurons), (ENO2, ST18 = early 
neural progenitors), (FAM107A, HOPX = outer radial glia), (SMOC1, S100B = intermediate progenitors) (CDK1, 
CDC20, MKI67 = proliferating progenitors) (CXCL14 = choroid/Astro). B. Heatmap of the overlaps between marker 
genes characterizing the internal organoids clusters and external gene signatures of the relevant single cell clusters 
from human fetal brains (Nowakowski et al., 2017). Colors are based on the log2Enrichment computed for each pair 
of comparisons. * indicates an overlap with p-value < 0.05. 
 
Figure S5. UMAP plots for proliferation/maturity distribution and pseudotime decomposition. Related to 
Figure 6. A. Visualization of expression levels of proliferation/progenitor markers (in red: CDK1, MKI67) coupled 
with maturity markers (in green: DCX, STMN2), (in yellow: overlapping expression). UMAPS are visualized 
separately for each timepoint and condition. B.  First and second components inferred from condition-wise diffusion 
components and visualized as color gradient on UMAP. The two extremes of the color scale (origin-blue and dark 
red-outcome) represent the distance in the relative diffusion component. CTL D100 is the only condition with an end 
point in oRG area. 
2. Supplemental experimental procedures 
hPSC culture. hPSC lines were cultured under feeder-free conditions on Matrigel (BD Biosciences) coated dishes 
(diluted 1:40 matrigel:DMEM/F12) and grown in TesrTM E8TM medium (Stem Cell Technologies). Cells were 
passaged upon treatment with ReLeSR (Stem Cell Technologies). All differentiation procedures were performed on 
iPSC lines with at least 15 passages after reprogramming. Pluripotent lines came from different individuals 
representing either human iPSC or ESC lines previously described (Adamo et al., 2015; González et al., 2014). All 
the cultures were regularly tested and maintained mycoplasma free. 
Table 1. Distribution of hPSC lines used in this study. 










ICC  X X X X 
Rosette formation assay  X X X  
Growth curve   X X X 
Bulk RNAseq X X X X X 
Single cell RNAseq X X X X X 
 
Neural induction and lumen quantification. hPSC cells were plated at a density of 0.7 × 105 cells cm2 on Matrigel 
(BD Biosciences) coated dishes in grow medium supplemented with 10 µM ROCK inhibitor (Y-2763221, Cell 
Guidance System). Cell cultures were expanded for two days until they were 70% confluent. The starting 
differentiation medium includes DMEM/F12 (Life Technologies) with N2 and B27 without retinoic acid (Life 
Technologies), supplemented with 500 nM LDN193189 (Sigma) and 10 µM SB431542 (Tocris). Cells were fixed at 
day 20 in 4% (wt/vol) paraformaldehyde (PFA) for 15 minutes at room temperature (RT) and washed 3 times with 
phosphate-buffered saline (PBS). Cells were then permeabilized with PBS containing 0.5% Triton X-100 (Sigma) and 
blocked with 10% (vol/vol) normal goat serum (NGS; Vector) for 1 hour at RT. Next, cells were incubated overnight 
at 4°C. The following primary antibodies and dilutions were used: Anti-PALS1, (Proteintech 117710-1-AP). Object 
identification module of Cell Profiler software (v.2.1.1) was used to automatically quantify lumens (number and size 
of Pals1 positive areas) of neural rosettes. 
Cortical organoid protocol. hPSCs were plated onto cell cycle-arrested mouse embryonic feeders (MEFs)(Millipore) 
for one passage, colonies grown for at least 48h and then enzymatically detached by incubation with 0.7 mg/ml dispase 
(Invitrogen: 17105-041) for approx. 30 min. Suspended colonies were subsequently transferred into ultra-low-
attachment 100 mm plastic plates (Corning) in FGF2-free knockout serum medium. For the first 24 h (day 0), the 
medium was supplemented with the ROCK inhibitor Y-27632 (EMD Chemicals). For neural induction, dorsomorphin 
(Merck, 5 μM) and SB-431542 (Tocris, 10 μM) were added to the medium until day 5. From day 6 onward, organoids 
were moved to neural medium (NM) containing Neurobasal (Invitrogen 10888), B-27 serum substitute without 
vitamin A (Invitrogen 12587), GlutaMax 1:100 (Fisher 35050071), 100 U/ml penicillin and streptomycin (Invitrogen) 
and 50 mM b-Mercaptoethanol (Gibco 31350010). The NM was supplemented with 20 ng/ml FGF2 (Thermo) and 20 
ng/ml EGF (Tocris) for 19 days with daily medium change in the first 10 days, and every other day for the subsequent 
9 days. On day 12, floating organoids were moved to orbital shaker (VWR Standard Orbital Shaker, Model 1000) and 
kept on constant shaking at 50 rpm to promote nutrient and oxygen exchange. To induce neurogenesis, FGF2 and 
EGF were replaced with 20 ng/ml BDNF (Peprotech) and 20 ng/ml NT3 (Peprotech) starting at day 25, while from 
day 43 onwards only NM without growth factors was used for medium changes every other day. 
Primary and secondary antibodies used and quantifications. Primary antibodies were prepared in PBS + 5% 
normal donkey serum (Jackson Immuno Resarch) overnight at 4°C. The following primary antibodies and dilutions 
were used: anti-PAX6, 1:200 (Biolegend PRB-278B); anti-KI67, 1:200 (Abcam ab15580); anti-NESTIN, 1:500 
(Millipore MAB5326); anti–DCX, 1:1000 (BD Biosciences 611706); anti-TBR1, 1:200 (Abcam ab31940), anti-
HOPX, 1:50 (Sigma-Aldrich HPA030180), Anti CTIP2 1:200 (Abcam ab18465). After primary incubation, sections 
were washed three times with PBS and the incubated with appropriate secondary antibodies: anti-rabbit Alexa 488-
conjugated (Bethyl  A090-516D2)  anti-mouse, Alexa 594-conjugated (Bethyl  A110-305B4) (Molecular Probes, 
Invitrogen) diluted 1:500 in blocking solution and incubated for 2 h at RT. Before mounting, sections were incubated 
with Hoechst 33258 (5 μg/mL; Molecular Probes, Invitrogen) or DAPI 1:5000 (Merck), as indicated on each caption. 
Quantification of nuclear markers was done by using the automatic cluster counter ITCN plugin from FIJI (v.1.49 
NIH-USA) for at least 3 organoids from 3 independent lines. Images were RGB converted and cluster counts were 
done over pre-defined concentric grids from VLS. The relative number of positive cells was calculated as a percentage 
of total DAPI+ cells. Images were acquired with a Leica DMI 6000B microscope (10x, 20x and 40x objectives) and 
analyzed with LAS-AF imaging software and then processed using Image J (v1.49 NIH, USA) to adjust contrast for 
optimal RGB rendering. Semi-quantitative measurements were made in imageJ, the background noise was removed 
with a sliding paraboloid filter of dimension 500 px, then a gaussian filter was applied. A positive cell was considered 
the local maxima with a minimum threshold of signal to noise. To evaluate the density of cells we consider organoid 
slice stained with DAPI, from the images of the whole organoid we remove, with a sliding paraboloid filter, the 
background and then apply a common threshold on all the conditions. The area of the resulting mask is considered as 
area occupied by nuclei and used as normalization. 
Bulk transcriptome analysis. Differential gene expression. Gene expression quantification at the gene level was 
performed by Salmon (version 0.8.2) (Patro et al., 2017), using hg38 RefSeq annotation.  To estimate differential 
expression, the matrix of gene counts was analyzed by edgeR (version 3.20.9) (Robinson et al., 2009). For each time 
point, genes with an expression level of at least 2 cpm (count per million) in at least 3 samples were selected for the 
analysis. Small genes, ribosomal genes and fusion genes were excluded. After TMM normalization, differential 
expression analysis comparing treated to untreated samples was performed using a likelihood ratio test on the 
coefficients of a negative binomial model. Significantly modulated genes were selected setting an absolute value of 
log2 fold change (Log2FC) higher than 1 and a false discovery rate (FDR) lower than 5%. Log2 cpm values, were 
used for heatmap representation of gene expression profiles (visualized as z-scores). Heatmaps were produced with 
pheatmap R package (version 1.0.10, Raivo Kolde (2018). pheatmap: Pretty Heatmaps.). Analyses were performed in 
R version 3.4.4. Functional annotation of biological functions was performed by Gene ontology analysis and Gene set 
enrichment analysis (GSEA) using as set source H1 collection from the Molecular Signature Database (Liberzon et 
al., 2015). Gene Ontology Enrichment Analysis. Gene ontology enrichment analysis for the Cellular Component 
domain of the ontology was performed on the 898 DEGs identified at day 50, split in up-regulated and down-regulated 
genes. The pool of tested genes (as selected for differential expression analysis) was used as background. The analysis 
was performed by topGO (version 2.30.1) (Adrian Alexa and Jorg Rahnenfuhrer 2016). topGO: Enrichment Analysis 
for Gene Ontology), relying on Fisher test and Weight01 method to take into account ontology hierarchy; minimum 
node size was set at 15. After imposing an enrichment cut-off of 2, a 0.01 p-value cut off was applied to select 
significantly enriched GO terms. Barplot in supplementary figure 4 shows the top-10 categories ranked for p-value. 
Gene set enrichment analysis. GSEA was applied to each developmental stage with GSAA software, version 1.2 
(Xiong et al., 2014). Raw reads for the same genes tested for differential expression were analyzed by GSAASeqSP 
(permutation type ‘gene set’).  
 
Single cell library preparation and sequencing. Briefly, a small volume (6 - 8 μl) of single-cell suspension at a 
density of 1000 cells/μl was mixed with RT-PCR master mix and immediately loaded together with Single-Cell 3′ gel 
beads and partitioning oil into a single-cell 3′ Chip. The gel beads were coated with unique primers bearing 10× cell 
barcodes, unique molecular identifiers (UMI) and poly(dT) sequences. The chip was then loaded onto a Chromium 
instrument (10× Genomics) for single-cell GEM generation and barcoding. RNA transcripts from single cells were 
reverse-transcribed within droplets to generate barcoded full-length cDNA using Clontech SMART technology. After 
emulsion disruption, cDNA molecules from one sample were pooled and preamplified. Finally, amplified cDNAs 
were fragmented, and adapter and sample indices were incorporated into finished libraries which were compatible 
with Illumina sequencing. The final libraries were quantified by Qubit system (Thermo) and calibrated with an in-
house control sequencing library. The size profiles of the pre-amplified cDNA and sequencing libraries were examined 
by Agilent Bioanalyzer 2100 using a High Sensitivity DNA chip (Agilent). Two indexed libraries were equimolarly 
pooled and sequenced on Illumina NOVAseq 6000 platform using the v2 Kit (Illumina, San Diego, CA) with a 
customized paired-end, dual indexing format according to the recommendation by 10× Genomics. Using proper cluster 
density, a coverage around 250 M reads per sample (2000–5000 cells) were obtained corresponding to at least 50,000 
reads/cell. 
 
Single cell transcriptome analysis. Before downstream analyses, data deriving from the 11 samples was integrated 
by Seurat v3.0-alpha analytical framework (Stuart et al., 2018). After normalization, anchors for data integration were 
identified considering 3000 anchor points (genes) and 40 dimensions. For data reduction, UMAP was applied with 50 
nearest neighbors (nn); cluster initial positions were set considering PAGA node position (Scanpy v1.3.1) (Wolf et 
al., 2018). On the integrated dataset, clusters were identified by applying Louvain with Multilevel Refinement from 
Seurat with resolution parameter at 0.7. This resulted in the identification of 15 clusters. For cluster annotation, we 
applied the FindMarker Seurat function, using MAST as test and filtering for up-regulated genes with adjusted P value 
< 0.05. The obtained lists were compared in an overlap analysis with gene lists derived from two published single cell 
datasets: from the WGCNA analysis of single cell clusters of human fetal brains (paper by Nowakowski et al, DOI: 
10.1126/science.aap8809), data were downloaded from the web portal at https://cells.ucsc.edu/?ds=cortex-dev and 
upregulated genes (vg_diff.float>1.5) were selected for each relevant cluster, from the differential expression analysis 
of single nuclei clusters (Table S6 of the paper by Amiri et al, DOI: 10.1126/science.aat6720), upregulated genes (fold 
change > 0 and adjusted P value < 0.05) were selected for each relevant cluster. P values and enrichment coefficients 
were computed relative to a universe of 3000 genes used for all the other single cell analysis. Cluster-specific 
expression levels of biologically-relevant genes identified among the top dysregulated were visualized by violin plots, 
stratified for stage and treatment. To test for unbalance in the number of highly expressing cells for representative 
genes per cluster or cluster set, a threshold of expression at the 90th percentile was fixed, and the number of cells 
above or below the threshold in treated and untreated cells was compared by Fisher test. The identification of the 
threshold and sub-sequent analysis was performed on the sub-sampled dataset, separately for Day 50 and Day 100.  
Cell cycle analysis were performed using Scanpy function score_genes_cell_cycle, relying on the genes from 
(Kowalczyk et al., 2015). Diffusion map algorithm for dimensionality reduction was performed with Scanpy with 50 
nn.  Pseudotime analysis for lineage branching reconstruction was applied using wishbone algorithm (Setty et al., 
2016). The analysis was performed on the complete dataset, as well as separately for each of the four biological 
conditions in order to infer stage or treatment-selective trajectories; the origin was identified with the same method 
applied on complete dataset. Trajectories were reproduced defining using at least 3 different markers. Partition-based 
graph abstraction (PAGA) algorithm was applied on the complete dataset, as well as separately for each of the four 
biological conditions and plotted with layout Reingold Tilford. The position of the nodes identified on the complete 
dataset was exploited in the graph for each biological condition. 
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